Outlook Therapeutics, Inc. 8-K

What Happened

• On May 26, 2026 Outlook Therapeutics announced the FDA granted its appeal following completion of the Formal Dispute Resolution (FDR) process related to the December 30, 2025 Complete Response Letter (CRL) for the Biologics License Application (BLA) for ONS-5010/LYTENAVA™ (bevacizumab-vikg) for neovascular age-related macular degeneration (nAMD).
• The FDA concluded that substantial evidence of effectiveness has been established for LYTENAVA™ and directed the Division of Ophthalmology and the Office of Specialty Medicine to work with the company to reach agreement on final labeling. Outlook expects to resubmit the BLA in June 2026 as a Class 1 resubmission. The company issued a press release on May 26, 2026 (attached as Exhibit 99.1).

Key Details

• Date of appeal decision: May 26, 2026.
• Original CRL date: December 30, 2025.
• Product: ONS-5010 / LYTENAVA™ (bevacizumab-vikg) for nAMD.
• Planned regulatory step: BLA resubmission in June 2026 as a Class 1 resubmission.

Why It Matters

• This FDA appeal win reverses the agency’s earlier negative outcome in the December 2025 CRL on the question of effectiveness, removing a major regulatory obstacle for LYTENAVA™.
• The FDA’s direction to negotiate final labeling with the company and Outlook’s planned timely resubmission are material developments that could advance the application toward potential approval, which would be a key commercial milestone for the company and relevant to investors monitoring regulatory risk and commercialization prospects.